

Made for conjugation

Mobius® ADC Reactor with Single-Use Technology

Making the switch to single-use for conjugation

While there is a general shift toward single-use technologies among mAb manufacturers, the adoption for Antibody Drug Conjugate manufacturing steps is not as common. Facilities are hesitant to adopt single-use methods because they have concerns about compatibility, quality and safety. But sticking with stainless steel or glass manufacturing methods has many limitations.

The limitations of stainless steel or glass manufacturing methods

- Extensive cleaning and sterilization between runs
- Underutilized equipment and costly facility expansions
- Resource intensive methods
- Negative environmental impact
- Difficult to respond quickly to changing demands

The **Mobius® ADC Reactor** allows for flexible manufacturing that reduces risk, is compatible with your existing workflow, and reduces waste for maximum efficiency.



Ultimus[®] Film Superior film resistance with Ultimus film

No drip no splash with reagent dip tubes



Flexible Manufacturing




Linear Scale-up with the Mobius[®] ADC Reactor Accommodates varying

Preserved product quality with gentle mAb addition via side port



batch sizes, adapting to ADC development phases, and enables smooth scale-up.



30% Risk Reduction

95% 70% Potent Liquid Waste Reduction Efficiency

Learn more about the Mobius® ADC Reactor SigmaAldrich.com/ADC-reactor

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck, Millipore, Ultimus, Mobius and the Vibrant M are trademarks of Merck KGaA, Darmstadt, Germany and/or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. © 2024 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Lit No. MK_FL13584EN 06/2024 V1.0

Millipore。

Expert Pharm/BioPharm Products & CTDMO Services